University Officials Struggle To Find True Price Of Science

Indirect costs scandals and a new federal mandate pressure budget officers to grapple with what they see as a befuddling to grapple with what they see as a befuddling task WASHINGTON--University research administrators across the United States are moving to comply with a newly imposed limit on how much money they can recover from the government to compensate their schools for administrative support of federally funded research. And in the process of observing the new federal regulation,

Written byJeffrey Mervis
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

Indirect costs scandals and a new federal mandate pressure budget officers to grapple with what they see as a befuddling to grapple with what they see as a befuddling task

WASHINGTON--University research administrators across the United States are moving to comply with a newly imposed limit on how much money they can recover from the government to compensate their schools for administrative support of federally funded research.

And in the process of observing the new federal regulation, some of these administrators are becoming frustrated by what they see as a fundamental flaw in the system of indirect costs recovery--namely, the lack of consensus on how to calculate the real cost of research at their institutions.

"For all the accounting that goes into it, it's still not a precise science," says Marvin Ebel, a physicist and associate dean of the graduate school at the University of Wisconsin, Madison, referring to the ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies